Asymchem Laboratories Tian Jin Co Ltd Market Cap ($6.56 Billion)
Market Cap & Net Worth: Asymchem Laboratories Tian Jin Co Ltd (002821)
Asymchem Laboratories Tian Jin Co Ltd market cap. Asymchem Laboratories Tian Jin Co Ltd (SHE:002821) has a market capitalization of $6.56 Billion (CN¥44.82 Billion) as of November 1, 2026. Listed on the SHE stock exchange, this China-based company holds position #2891 globally and #312 in its home market, demonstrating a -3.62% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Asymchem Laboratories Tian Jin Co Ltd's stock price CN¥134.61 by its total outstanding shares 332946460 (332.95 Million). Also see Asymchem Laboratories Tian Jin Co Ltd (002821) cash conversion ratio for how efficiently the company converts equity into cash flow.
Asymchem Laboratories Tian Jin Co Ltd Market Cap History (2016–2026)
Asymchem Laboratories Tian Jin Co Ltd market cap history from 2016 to 2026. Data shows growth from $2.35 Billion to $6.56 Billion (24.87% CAGR). Check 002821 stock price for real-time trading data and today's change.
Asymchem Laboratories Tian Jin Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Asymchem Laboratories Tian Jin Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore how fast is Asymchem Laboratories Tian Jin Co Ltd growing its equity to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.68x
Asymchem Laboratories Tian Jin Co Ltd's market cap is 0.68 times its annual revenue
Latest Price to Earnings (P/E) Ratio
4.00x
Asymchem Laboratories Tian Jin Co Ltd's market cap is 4.00 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $2.35 Billion | $1.10 Billion | $252.74 Million | 2.13x | 9.29x |
| 2017 | $1.96 Billion | $1.42 Billion | $341.29 Million | 1.38x | 5.76x |
| 2018 | $2.24 Billion | $1.83 Billion | $428.30 Million | 1.22x | 5.22x |
| 2019 | $4.29 Billion | $2.46 Billion | $553.86 Million | 1.74x | 7.74x |
| 2020 | $9.93 Billion | $3.14 Billion | $719.74 Million | 3.17x | 13.80x |
| 2021 | $14.46 Billion | $4.63 Billion | $1.07 Billion | 3.12x | 13.53x |
| 2022 | $6.92 Billion | $10.23 Billion | $3.30 Billion | 0.68x | 2.10x |
| 2023 | $5.51 Billion | $7.83 Billion | $2.27 Billion | 0.70x | 2.43x |
| 2024 | $3.71 Billion | $5.80 Billion | $948.95 Million | 0.64x | 3.91x |
| 2025 | $4.53 Billion | $6.67 Billion | $1.13 Billion | 0.68x | 4.00x |
Competitor Companies of 002821 by Market Capitalization
Companies near Asymchem Laboratories Tian Jin Co Ltd in the global market cap rankings as of November 1, 2026. Also see total assets of Asymchem Laboratories Tian Jin Co Ltd for a full breakdown of the balance sheet.
Key companies related to Asymchem Laboratories Tian Jin Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Asymchem Laboratories Tian Jin Co Ltd (2016–2026)
Market capitalization of Asymchem Laboratories Tian Jin Co Ltd from 2016 to today. Between 2016 and today, Asymchem Laboratories Tian Jin Co Ltd's market cap moved from $2.35 Billion to $ 6.56 Billion, with a yearly change of 24.87%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥6.56 Billion | +44.85% |
| 2025 | CN¥4.53 Billion | +22.13% |
| 2024 | CN¥3.71 Billion | -32.67% |
| 2023 | CN¥5.51 Billion | -20.41% |
| 2022 | CN¥6.92 Billion | -52.17% |
| 2021 | CN¥14.46 Billion | +45.65% |
| 2020 | CN¥9.93 Billion | +131.49% |
| 2019 | CN¥4.29 Billion | +91.75% |
| 2018 | CN¥2.24 Billion | +13.86% |
| 2017 | CN¥1.96 Billion | -16.30% |
| 2016 | CN¥2.35 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Asymchem Laboratories Tian Jin Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $6.56 Billion USD |
| MoneyControl | $6.56 Billion USD |
| MarketWatch | $6.56 Billion USD |
| marketcap.company | $6.56 Billion USD |
| Reuters | $6.56 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Asymchem Laboratories Tian Jin Co Ltd
Asymchem Laboratories (Tianjin) Co., Ltd. provides contract development and manufacturing organization (CDMO) solutions in Mainland China and internationally. It is involved in small molecule CDMO services for projects covering multiple major disease treatment areas, such as oncology, antiviral, anti-infective, cardiovascular, and diabetes; chemical macromolecule CDMO; biomacromolecule CDMO, incl… Read more